Subtopic Deep Dive

TREM-1 in Sepsis Pathophysiology
Research Guide

What is TREM-1 in Sepsis Pathophysiology?

TREM-1 (Triggering Receptor Expressed on Myeloid cells-1) is a transmembrane receptor on neutrophils and monocytes that amplifies inflammatory responses in sepsis pathophysiology.

TREM-1 enhances degranulation and proinflammatory cytokine secretion during septic shock (Bouchon et al., 2001, 1085 citations). Soluble TREM-1 (sTREM-1) serves as a biomarker for bacterial infections like pneumonia in ventilated patients (Gibot et al., 2004, 629 citations). Over 10 papers in the provided list highlight its role in sepsis from 2001-2023.

Curated Papers

Key Challenges

Why It Matters

TREM-1 blockade reduces mortality in murine sepsis models by modulating inflammatory responses (Gibot et al., 2004, 362 citations). Elevated sTREM-1 in bronchoalveolar lavage fluid diagnoses bacterial pneumonia, aiding rapid ICU decisions (Gibot et al., 2004, 629 citations). TREM-1 amplification contributes to septic shock progression, positioning it as a therapeutic target (Bouchon et al., 2001, 1085 citations). Reviews confirm its consistent elevation in sepsis cohorts (Pierrakos and Vincent, 2010, 1318 citations).

Key Research Challenges

sTREM-1 Diagnostic Specificity

sTREM-1 levels rise in bacterial pneumonia but lack specificity against viral or sterile inflammation (Gibot et al., 2004, 629 citations). Recent reappraisals question its standalone diagnostic value in heterogeneous sepsis (Pierrakos et al., 2020, 637 citations). Validating cutoffs across patient populations remains unresolved.

Therapeutic Blockade Efficacy

TREM-1 inhibition attenuates inflammation in murine sepsis, but human trials show variable outcomes (Gibot et al., 2004, 362 citations). Translating preclinical blockade to clinical septic shock faces dosing and timing hurdles (Bouchon et al., 2001, 1085 citations). Long-term immunomodulation risks persist.

Pathway Crosstalk Mechanisms

TREM-1 interacts with DAMPs and NETs in sepsis, but precise signaling overlaps with other receptors need mapping (Denning et al., 2019, 584 citations). Chronic inflammation roles extend beyond acute sepsis (Schenk et al., 2007, 366 citations). Integrating multi-omics data for pathway models is challenging.

Essential Papers

Sepsis biomarkers: a review

Charalampos Pierrakos, Jean‐Louis Vincent · 2010 · Critical Care · 1.3K citations

TREM-1 amplifies inflammation and is a crucial mediator of septic shock

Axel Bouchon, Fabio Facchetti, Markus A. Weigand et al. · 2001 · Nature · 1.1K citations

Biomarkers of sepsis: time for a reappraisal

Charalampos Pierrakos, Dimitrios Velissaris, Max Bisdorff et al. · 2020 · Critical Care · 637 citations

Soluble Triggering Receptor Expressed on Myeloid Cells and the Diagnosis of Pneumonia

Sébastien Gibot, Aurélie Cravoisy, Bruno Lévy et al. · 2004 · New England Journal of Medicine · 629 citations

In patients receiving mechanical ventilation, rapid detection of sTREM-1 in bronchoalveolar-lavage fluid may be useful in establishing or excluding the diagnosis of bacterial or fungal pneumonia.

DAMPs and NETs in Sepsis

Naomi‐Liza Denning, Monowar Aziz, Steven D. Gurien et al. · 2019 · Frontiers in Immunology · 584 citations

Sepsis is a deadly inflammatory syndrome caused by an exaggerated immune response to infection. Much has been focused on host response to pathogens mediated through the interaction of pathogen-asso...

TREM-1–expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases

Mirjam Schenk, Axel Bouchon, Frank Seibold et al. · 2007 · Journal of Clinical Investigation · 366 citations

Triggering receptor expressed on myeloid cells-1 (TREM-1) potently amplifies acute inflammatory responses by enhancing degranulation and secretion of proinflammatory mediators. Here we demonstrate ...

A Soluble Form of the Triggering Receptor Expressed on Myeloid Cells-1 Modulates the Inflammatory Response in Murine Sepsis

Sébastien Gibot, Marie‐Nathalie Kolopp‐Sarda, Marie-C. Béné et al. · 2004 · The Journal of Experimental Medicine · 362 citations

The triggering receptor expressed on myeloid cells (TREM)-1 is a recently discovered receptor expressed on the surface of neutrophils and a subset of monocytes. Engagement of TREM-1 has been report...

Reading Guide

Foundational Papers

Start with Bouchon et al. (2001, 1085 citations) for TREM-1's core role in septic shock amplification, then Gibot et al. (2004, 629 citations) for sTREM-1 biomarker validation, followed by Pierrakos and Vincent (2010, 1318 citations) for sepsis context.

Recent Advances

Study Pierrakos et al. (2020, 637 citations) for biomarker reappraisal, Denning et al. (2019, 584 citations) for DAMPs integration, and Colonna (2023, 318 citations) for TREM biology advances.

Core Methods

Core techniques: sTREM-1 detection via ELISA in fluids (Gibot et al., 2004), TREM-1 knockout/blockade in mice (Gibot et al., 2004; Bouchon et al., 2001), and cytokine profiling post-TREM-1 engagement.

How PapersFlow Helps You Research TREM-1 in Sepsis Pathophysiology

Discover & Search

Research Agent uses searchPapers and exaSearch to retrieve core papers like 'TREM-1 amplifies inflammation and is a crucial mediator of septic shock' (Bouchon et al., 2001). citationGraph reveals forward citations from Pierrakos and Vincent (2010, 1318 citations) to recent reviews, while findSimilarPapers uncovers sTREM-1 biomarker analogs.

Analyze & Verify

Analysis Agent employs readPaperContent on Gibot et al. (2004, 629 citations) to extract sTREM-1 sensitivity/specificity data, then runPythonAnalysis with pandas to meta-analyze biomarker levels across Pierrakos papers. verifyResponse (CoVe) and GRADE grading verify claims like TREM-1's septic shock mediation against contradictions in Denning et al. (2019).

Synthesize & Write

Synthesis Agent detects gaps in TREM-1 human trials via gap detection on Bouchon et al. (2001) and Gibot et al. (2004), flagging blockade translation needs. Writing Agent uses latexEditText, latexSyncCitations for sepsis pathway figures, and latexCompile to generate review manuscripts with exportMermaid diagrams of TREM-1 signaling.

Use Cases

"Extract and plot sTREM-1 levels from Gibot 2004 and Pierrakos sepsis papers"

Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib plot of biomarker concentrations) → CSV export of meta-analyzed levels with GRADE scores.

"Draft LaTeX review on TREM-1 blockade in septic shock citing Bouchon 2001"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (auto-inserts Bouchon et al., Gibot et al.) + latexCompile → PDF manuscript with TREM-1 pathway diagram.

"Find code for TREM-1 signaling simulations from related papers"

Research Agent → citationGraph on Colonna 2023 → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → Python scripts modeling TREM-1/DAP12 interactions.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (TREM-1 sepsis) → citationGraph → DeepScan (7-step analysis of Bouchon 2001 + Gibot 2004) → structured report with GRADE tables. Theorizer generates hypotheses on sTREM-1 + DAMPs crosstalk from Denning et al. (2019). Chain-of-Verification/CoVe ensures biomarker claim accuracy across Pierrakos reviews.

Try Doxa for TREM-1 in Sepsis Pathophysiology Research

Frequently Asked Questions

What is the definition of TREM-1 in sepsis?

TREM-1 is an amplifying receptor on myeloid cells that boosts cytokine release and inflammation in septic shock (Bouchon et al., 2001).

What are key methods for studying TREM-1?

Methods include sTREM-1 ELISA in bronchoalveolar lavage for pneumonia diagnosis (Gibot et al., 2004) and TREM-1 blockade in murine sepsis models (Gibot et al., 2004).

What are the most cited papers on TREM-1 sepsis?

Top papers: Bouchon et al. (2001, 1085 citations) on septic shock mediation; Gibot et al. (2004, 629 citations) on sTREM-1 diagnostics; Pierrakos and Vincent (2010, 1318 citations) review.

What are open problems in TREM-1 research?

Challenges include sTREM-1 specificity in mixed infections, human trial efficacy of blockade, and pathway integration with DAMPs/NETs (Pierrakos et al., 2020; Denning et al., 2019).